Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy

Table 2 Statistical evaluation of the tumor-specific and chemotherapy response-related gene expression signatures.

Gene	Tumor vs. Normal		Poor vs Good		References
	p-value	fold change	p-value	fold change
RECQL4	0.00087	10.16	0.84739	-1.14	[22]*
DOCK5	0.00094	-36.81	0.86960	-1.58	[18]
SPP1	0.00180	113.97	0.57674	-1.21	[18]
RUNX2	0.00222	7.13	0.02782	3.30	[18]
RB1	0.00252	-14.87	0.14164	5.14	[16]
CDKN1A	0.00409	-8.61	0.71798	1.27	[18]
P53	0.00409	-20.63	0.45016	1.65	[12–15]
IBSP	0.03382	9.61	0.45016	-1.25	[18]
LSAMP	0.04278	-11.56	0.14164	4.42	[18]
MYC	0.05492	3.05	0.56370	1.61	[17]
TNFRSF10A	0.07359	-2.34	1.00000	-1.07	[18]
BMP2	0.10975	3.86	0.36911	2.21	[18]
HISTH2BE	0.26121	1.30	0.97381	1.10	[18]
FOS	0.33725	2.34	0.56763	2.95	[19, 20]
CCNB1	0.41368	-1.20	0.46243	-1.03	[18]
CDC5L	0.90645	-1.13	0.63043	-1.98	[21]

*References are to the original papers describing the change in expression in these genes in osteosarcoma

ISSN: 1471-2407